Antroquinonol (Hocena), an anti-cancer and anti-hyperlipidemia drug developed by a Taiwanese firm as a potential medicine to treat COVID-19, was approved by Peru's authorities to begin phase II trials, according to its developer.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Taiwan shares close up 0.34%
07/31/2025 02:06 PM - Politics
Taiwan, U.S. complete 'technical consultations' on trade: Cabinet
07/31/2025 02:02 PM - Society
2 dead, 3 critical in Taichung beef noodle shop fire
07/31/2025 01:31 PM - Society
Heavy rain to continue in central, southern Taiwan Thursday: CWA
07/31/2025 12:57 PM - Science & Tech
Taiwan to launch 3 locally made CubeSats in October
07/31/2025 11:00 AM